A Multicenter, Randomized, Open-label Parallel Group Pilot Study to Evaluate Safety and Efficacy of High Dose Intravenous Immune Globulin (IVIG) Plus Standard Medical Treatment (SMT) Versus SMT Alone in Subjects With COVID-19 Requiring Admission to the Intensive Care Unit
Latest Information Update: 10 Oct 2022
At a glance
- Drugs Immune globulin (Primary)
- Indications COVID 2019 infections
- Focus Adverse reactions
- Sponsors Grifols
- 10 Nov 2021 Status changed from active, no longer recruiting to completed.
- 09 Aug 2021 Planned primary completion date changed from 1 Jul 2021 to 1 Aug 2021.
- 09 Aug 2021 Status changed from recruiting to active, no longer recruiting.
Most Recent Events
Trial Overview
Purpose
The purpose of the study is to determine if a high dose of Intravenous Immune Globulin (IVIG) plus Standard Medical Treatment (SMT) can reduce all-cause mortality versus SMT alone in hospitalized participants with COVID-19 requiring admission to the ICU through Day 29.
Primary Endpoints
All-Cause Mortality Rate Through Day 29
description: All-cause mortality rate is percentage of participants in each treatment group who experienced mortality up to Day 29.
time_frame: Up to Day 29
Other Endpoints
Percentage of Participants With Actual Intensive Care Unit (ICU) Discharge Time
description: Percentage of participants who were discharged from ICU were recorded. Time to actual ICU discharge was defined as duration of actual ICU stay from Day 1 through Day 29.
time_frame: Up to Day 29
Duration of Mechanical Ventilation
description: Duration (number of days) of ICU stay from post-randomization through Day 29 was calculated based on ICU admission and discharge (actual and medical equivalence) dates.
time_frame: Up to Day 29
Percentage of Participants With Actual Hospital Discharge Time
description: Percentage of participants who were discharged from the hospital were recorded. Time to hospital discharge was defined as duration of hospitalization from Day 1 through Day 29.
time_frame: Up to Day 29
Duration of Any Oxygen Use From Day 1 Through Day 29
description: Duration (number of days) of any oxygen use from Day 1 through Day 29 was calculated based on the start/stop dates.
time_frame: Up to Day 29
Mean Change From Baseline in Ordinal Scale
description: The ordinal scale is a 7-point scale ranging from 1 to 7 used to measure clinical status based on the following points: 1) Death; 2) Hospitalized, on invasive mechanical ventilation or extracorporeal membrane oxygenation (ECMO) 3) Hospitalized, on non-invasive ventilation or high flow oxygen devices; 4) Hospitalized, requiring supplemental oxygen; 5) Hospitalized, not requiring supplemental oxygen; 6) Not hospitalized, limitation on activities; 7) Not hospitalized, no limitations on activities. Higher score indicated no severe illness. Mean change in Ordinal scale was evaluated by fitting a linear mixed-effects model for repeated measures (MMRM). The data is reported for average across all postbaseline.
time_frame: Baseline up to Day 29
Absolute Change From Baseline in Ordinal Scale at Day 29
description: The ordinal scale is a 7-point scale ranging from 1 to 7 used to measure clinical status based on the following points: 1) Death; 2) Hospitalized, on invasive mechanical ventilation or extracorporeal membrane oxygenation (ECMO) 3) Hospitalized, on non-invasive ventilation or high flow oxygen devices; 4) Hospitalized, requiring supplemental oxygen; 5) Hospitalized, not requiring supplemental oxygen; 6) Not hospitalized, limitation on activities; 7) Not hospitalized, no limitations on activities. Higher score indicated no severe illness.
time_frame: Baseline, Day 29
Percentage of Participants in Each Severity Category of the 7-Point Ordinal Scale
description: The ordinal scale is a 7-point scale ranging from 1 to 7 used to measure clinical status based on the following points: 1) Death; 2) Hospitalized, on invasive mechanical ventilation or extracorporeal membrane oxygenation (ECMO) 3) Hospitalized, on non-invasive ventilation or high flow oxygen devices; 4) Hospitalized, requiring supplemental oxygen; 5) Hospitalized, not requiring supplemental oxygen; 6) Not hospitalized, limitation on activities; 7) Not hospitalized, no limitations on activities.
time_frame: Days 15 and 29
Percentage of Participants Who Develop Acute Respiratory Distress Syndrome (ARDS)
description: Acute Respiratory Distress Syndrome was defined based on Berlin criteria (chest imaging, origin of edema, oxygenation).
time_frame: Days 1, 5, 15 and 29
Percentage of Participants Who Develop ARDS Distributed by Severity
description: ARDS was defined by Berlin's criteria as: 1) Timing is usually within 1 week of a known clinical insult or new or worsening respiratory symptoms 2) Chest imaging: bilateral opacities-not fully explained by effusions, lobar/lung collapse, or nodules 3) Respiratory failure not fully explained by cardiac failure or fluid overload Need objective assessment (eg, echocardiography) to exclude hydrostatic edema if no risk factor present 4) Oxygenation: Mild 200 mm Hg < partial pressure of oxygen/fraction of inspired oxygen (PaO2/FiO2) ≤ 300 mm Hg with positive end-expiratory pressure (PEEP) or continuous positive airway pressure (CPAP) ≥ 5 cm H2Oc; Moderate 100 mm Hg < PaO2/FIO2 ≤ 200 mm Hg with PEEP ≥ 5 cm H2O; Severe PaO2/FIO2 ≤100 mm Hg with PEEP ≥ 5 cm H2O.
time_frame: Days 1, 5, 15 and 29
Change From Baseline in Sequential Organ Failure Assessment (SOFA) Score at Day 5, Day 15, and Day 29
description: SOFA score is a mortality prediction score that is based on the degree of dysfunction of six organ systems. The score is calculated on admission and every 24 hours until discharge using the worst parameters measured during the prior 24 hours SOFA score ranges from 0 (no organ dysfunction) to 24 (highest possible score / organ dysfunction). Higher score indicated severe illness.
time_frame: Days 5, 15, and 29
Change From Baseline in National Early Warning Score (NEWS)
description: NEWS is clinical scoring developed to improve detection of deterioration in ill participant. It is based on 7 clinical parameters: respiration rate, oxygen saturation, supplemental oxygen, systolic blood pressure (BP), pulse rate, level of consciousness, and temperature. A score of 0 and 2 was allocated to supplemental oxygen, 0 and 3 for level of consciousness and score of 0, 1, 2 and 3 for remaining parameters (i.e. respiration rate, oxygen saturation, systolic BP, pulse rate and temperature) where 0 = normal health condition to 3 = worst health condition; higher score indicated more severity. All scores were summed to get an aggregate score. Aggregate NEWS score ranged from 0 to 20, with higher scores meaning more severity/higher risk.
time_frame: Baseline and Day 29
Percentage of Participants Achieving Clinical Response: NEWS ≤ 2 Maintained for 24 Hours
description: Percentage of participants who achieved clinical response (i.e the NEWS score ≤2 maintained for 24 hours from Day 1 through Day 29) was estimated using the Kaplan-Meier method.
time_frame: Day 29 [1]
Diseases Treated
Indication | Qualifiers | Patient Segments |
---|---|---|
COVID 2019 infections | treatment | - |
Biomarker
NCT Number | Biomarker Name | Biomarker Function |
---|---|---|
NCT04480424 | C-reactive protein (CRP) | Eligibility Criteria |
D-dimer | Eligibility Criteria | |
Factor V | Eligibility Criteria | |
Ferritin | Eligibility Criteria | |
Prothrombin (PT) | Eligibility Criteria |
Subjects
- Subject Type patients
-
Number
Planned: 100
Actual: 100
- Sex male & female
- Age Group ≥ 18 years; adult
Patient Inclusion Criteria
- Hospitalized male or female subjects of ≥ 18 years of age at time of Screening who are being treated in the ICU for COVID-19 for not longer than 48 hours or for whom a decision has been made that COVID-19 disease severity warrants ICU admission. - Has laboratory-confirmed novel coronavirus {SARS-CoV-2} infection as determined by qualitative polymerase chain reaction (PCR) (reverse transcriptase [RT]-PCR), or other United States Food and Drug Administration (FDA)-approved diagnostic assay for COVID-19 in any specimen during the current hospital admission prior to randomization. - Illness (symptoms of COVID-19 of any duration requiring ICU level care), and the following: 1. Radiographic infiltrates by imaging (chest X-Ray, computerized tomography (CT) scan, etc.), and 2. Requiring mechanical ventilation and/or supplemental oxygen. - Any one of the following related to COVID-19: i. Ferritin > 400 nanogram per milliliter (ng/mL), ii. Lactate dehydrogenase (LDH) > 300 units per liter (U/L), iii. D-Dimers > reference range, or iv. C-reactive protein (CRP) > 40 milligram per liter (mg/L). - Subject provides informed consent prior to initiation of any study procedures.
Patient Exclusion Criteria
- Clinical evidence of any significant acute or chronic disease or pathophysiologic manifestations (eg, complications of COVID-19 standard medical treatments) that, in the opinion of the investigator, may place the subject at undue medical risk. - The subject has had a known (documented) serious anaphylactic reaction to blood, any blood-derived or plasma product or a past history of any hypersensitivity reactions to commercial immunoglobulin. - A medical condition in which the infusion of additional fluid is contraindicated. - Shock that is unresponsive to fluid challenge and/or multiple vasopressors and accompanied by multiorgan failure considered by the Principal Investigator not able to be reversed. - Subjects with known (documented) thrombotic complications to polyclonal IVIG therapy in the past. - Subjects with current or prior myocardial infarction, stroke, deep vein thrombosis, or thromboembolic event (within the past 12 months) or who have a history of thromboembolic events of unknown etiology. - Subjects with limitations of therapeutic effort. - Female subjects who are pregnant or of child-bearing potential with a positive test for pregnancy blood or urine human chorionic gonadotropin (HCG)-based assay at Screening/Baseline. - Subjects participating in another interventional clinical trial with investigational medical product or device. - Known history of prothrombin gene mutation 20210, homozygous Factor V Leiden mutations, antithrombin III deficiency, protein C deficiency, protein S deficiency or antiphospholipid syndrome. - Presence of malignancy (either new diagnosis of malignancy or known residual disease) within the past 12 months. - Creatinine at Screening is ≥ 4 mg/dL (or subject is dependent on dialysis/renal replacement therapy). - Known Immunoglobulin A (IgA) deficiency with anti-IgA serum antibodies. - Uncontrolled hypertension at the time of Screening (systolic blood pressure > 200 mm Hg) or refractory severe hypotension with sustained systolic blood pressure < 90 mm Hg unresponsive to vasopressors.
Trial Details
Identifiers
Identifier | Owner |
---|---|
NCT04480424 | ClinicalTrials.gov: US National Institutes of Health |
GC2007 | - |
Organisations
- Sponsors Grifols
- Affiliations Grifols
Trial Dates
-
Initiation Dates
Planned : 01 Jul 2020
Actual : 17 Sep 2020
-
Primary Completion Dates
Planned : 01 Aug 2021
Actual : 25 Aug 2021
-
End Dates
Planned : 01 Oct 2021
Actual : 25 Oct 2021
Other Details
- Design multicentre; open; parallel; prospective; randomised
- Phase of Trial Phase II
- Location USA
- Focus Adverse reactions
Interventions
Drugs | Route | Formulation |
---|---|---|
Immune globulinPrimary Drug | Intravenous | Infusion |
GAMUNEX-C + Standard Medical Treatment
Participants received 2 grams per kilogram (g/kg) of GAMUNEX-C, which was capped to a maximum of 160 g infusion intravenously (IV) for participants weighing more than 80 kg on Day 1. The 2 g/kg net total dose was divided either into infusions of 500 mg/kg body weight over 4 days or 400 mg/kg body weight over 5 days as per investigator's decision. Participants received standard of care interventions as per Principal Investigator's discretion from Day 1 up to Day 29. Biological: GAMUNEX-C (Intravenous Immune Globulin (Human), 10% Caprylate/Chromatography Purified.) Other Name: IGIV-C Drug: Standard Medical Treatment (SMT per local policies or guidelines.)
Standard Medical Treatment
Participants received all standard of care interventions required as per Principal Investigator's discretion throughout the participant's hospitalization, from Day 1 to Day 29. Drug: Standard Medical Treatment (SMT per local policies or guidelines.)
Trial Centres
Investigators
Investigator | Centre Name | Trial Centre Country |
---|---|---|
Christopher Provenzano, MD | McLaren Health Care-Macomb | USA |
Daniel Coulston, MD | MultiCare Deaconess Hospital | USA |
Elsa Mondou, MD
919-316-2079 elsa.mondou@grifols.com
show details
|
-
|
|
Franklin Rosenblat, MD | McLaren Health Care Oakland | USA |
Gerard Criner, MD | Temple University Hospital | USA |
John Youssef, MD | McLaren Flint | USA |
Kristopher Roach, MD | Chandler Regional Medical Center | USA |
Leon Tung, MD | CHRISTUS Health | USA |
Margaret Hagan, MD | Via Christi Research | USA |
Michael Tan, MD | Summa Health | USA |
Mohamed Saad, MD | University of Louisville | USA |
Monica Goldklang, MD | Columbia University Medical Center | USA |
Patricia Finn, MD | University of Illinois at Chicago | USA |
Rhonda Griffin
919-316-6693 rhonda.griffin@grifols.com
show details
|
-
|
|
Robert Plambeck, MD | CHI Health | USA |
Simon Mahler, MD | Wake Forest Baptist Medical Center | USA |
Steven Conrad, MD | Louisiana State University Health Sciences Center | USA |
Tarek Hassanein, MD | Southern California Research Center | USA |
Tiffany Dumont, MD | Allegheny Health Network Research Institute | USA |
Centres
Centre Name | Location | Trial Centre Country |
---|---|---|
- |
-
|
-
|
Allegheny Health Network Research Institute | Pittsburgh, Pennsylvania | USA |
Chandler Regional Medical Center | Chandler, Arizona | USA |
CHI Health | Omaha, Nebraska | USA |
CHRISTUS Health | Tyler, Texas | USA |
Columbia University Medical Center | New York, New York | USA |
Grifols Therapeutics LLC |
-
|
-
|
Louisiana State University Health Sciences Center | Shreveport, Louisiana | USA |
McLaren Flint | Flint, Michigan | USA |
McLaren Health Care Oakland | Pontiac, Michigan | USA |
McLaren Health Care-Macomb | Mount Clemens, Michigan | USA |
MultiCare Deaconess Hospital | Spokane, Washington | USA |
MultiCare Tacoma General Hospital | Tacoma, Washington | USA |
Southern California Research Center | Coronado, California | USA |
Summa Health | Akron, Ohio | USA |
Temple University Hospital | Philadelphia, Pennsylvania | USA |
University of Illinois at Chicago | Chicago, Illinois | USA |
University of Louisville | Louisville, Kentucky | USA |
Via Christi Research | Wichita, Kansas | USA |
Wake Forest Baptist Medical Center | Winston-Salem, North Carolina | USA |
Trial History
Event Date | Event Type | Comment |
---|---|---|
10 Oct 2022 | Other trial event | Last checked against Clinicaltrials.gov record. Updated 10 Oct 2022 |
10 Nov 2021 | Status change - completed | Status changed from active, no longer recruiting to completed. Updated 15 Nov 2021 |
10 Aug 2021 | Biomarker Update | Biomarkers information updated Updated 04 Nov 2021 |
09 Aug 2021 | Other trial event | Planned primary completion date changed from 1 Jul 2021 to 1 Aug 2021. Updated 12 Aug 2021 |
09 Aug 2021 | Status change - active, no longer recruiting | Status changed from recruiting to active, no longer recruiting. Updated 12 Aug 2021 |
30 Apr 2021 | Completion date | Planned End Date changed from 1 May 2021 to 1 Oct 2021. Updated 04 May 2021 |
30 Apr 2021 | Other trial event | Planned primary completion date changed from 1 Apr 2021 to 1 Jul 2021. Updated 04 May 2021 |
12 Nov 2020 | Completion date | Planned End Date changed from 1 Feb 2021 to 1 May 2021. Updated 18 Nov 2020 |
12 Nov 2020 | Other trial event | Planned primary completion date changed from 1 Dec 2020 to 1 Apr 2021. Updated 18 Nov 2020 |
21 Sep 2020 | Status change - recruiting | Status changed from not yet recruiting to recruiting. Updated 24 Sep 2020 |
23 Jul 2020 | Other trial event | New source identified and integrated (ClinicalTrials.gov: US National Institutes of Health: NCT04480424). Updated 23 Jul 2020 |
21 Apr 2020 | Other trial event | According to a Grifols media release, the company is leading this trial in collaboration with the U.S. Food and Drug Administration (FDA) and other health agencies. Updated 22 Apr 2020 |
30 Mar 2020 | New trial record | New trial record Updated 30 Mar 2020 |
25 Mar 2020 | Other trial event | According to a Grifols media release, the company will is collaborating with certain hospitals in the design of this study. Updated 30 Mar 2020 |
References
-
ClinicalTrials.gov: US National Institutes of Health. Trial-Reg 2023;.
Available from: URL: http://clinicaltrials.gov -
Grifols. Grifols Announces Formal Collaboration with US Government to Produce the First Treatment Specifically Targeting COVID-19. Media-Rel 2020;.
Media Release -
Grifols. Grifols maintains its operational levels and continues to reinforce its commitment to society. Media-Rel 2020;.
Media Release
Adis International Ltd. Part of Springer Science+Business Media
© Springer Nature Switzerland AG